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DObjectives: The Single Ventricle Reconstruction trial randomized 555 subjects with a single right ventricle un-
dergoing the Norwood procedure at 15 North American centers to receive either a modified Blalock-Taussig
shunt or right ventricle-to-pulmonary artery shunt. Results demonstrated a rate of death or cardiac transplanta-
tion by 12 months postrandomization of 36% for the modified Blalock-Taussig shunt and 26% for the right
ventricle-to-pulmonary artery shunt, consistent with other publications. Despite this high mortality rate, little
is known about the circumstances surrounding these deaths.
Methods: There were 164 deaths within 12 months postrandomization. A committee adjudicated all deaths for
cause and recorded the timing, location, and other factors for each event.
Results: The most common cause of death was cardiovascular (42%), followed by unknown cause (24%) and
multisystem organ failure (7%). The median age at death for subjects dying during the 12 months was 1.6
months (interquartile range, 0.6 to 3.7 months), with the highest number of deaths occurring during hospitali-
zation related to the Norwood procedure. The most common location of death was at a Single Ventricle Recon-
struction trial hospital (74%), followed by home (13%). There were 29 sudden, unexpected deaths (18%),
although in retrospect, 12 were preceded by a prodrome.
Conclusions: In infants with a single right ventricle undergoing staged repair, the majority of deaths within 12
months of the procedure are due to cardiovascular causes, occur in a hospital, and within the first few months of
life. Increased understanding of the circumstances surrounding the deaths of these single ventricle patients may
reduce the high mortality rate. (J Thorac Cardiovasc Surg 2012;144:907-14)Despite medical and surgical advances, patients with hypo-
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The Journal of Thoracic and Caventricle malformations experience the highest risk of mor-
tality of any common form of congenital heart disease.1-5
Staged palliation for these patients requires 3 procedures,
including the Norwood procedure at the time of birth,
a superior cavopulmonary anastomosis (stage II) at 4 to 6
months of age, and a Fontan procedure at age 12 to 48
months.
The Norwood procedure remains the procedure with the
highest risk of mortality during staged repair.1-4,6 It has
been postulated that the modified Blalock-Taussig shunt
(MBTS) traditionally used to supply pulmonary blood
flow at the Norwood procedure contributes to this high mor-
tality due to diastolic run-off into the pulmonary circulation
and ensuing coronary insufficiency.7,8 Alternatively, a right
ventricle-to-pulmonary artery shunt (RVPAS), as initially
described by Norwood in 1981 and recently popularized
by Sano and colleagues,4 can be utilized as the source of
pulmonary blood flow for the Norwood procedure. The
RVPAS does not result in continued forward flow during di-
astole, but requires an incision in the outflow tract of the
only functional ventricle.8 The 2 shunts have been com-
pared in small case series with limited follow-up that
demonstrated conflicting results for hospital survival.1-4,9rdiovascular Surgery c Volume 144, Number 4 907
Abbreviations and Acronyms
MBTS ¼ modified Blalock-Taussig shunt
RVPAS ¼ right ventricle-to-pulmonary artery shunt
SVR ¼ single ventricle reconstruction
Congenital Heart Disease Ohye et al
C
H
DThe Single Ventricle Reconstruction (SVR) trial (for a list
of participating centers and investigators, see Appendix 1)
(ClinicalTrials.gov unique identifier: NCT00115934) ran-
domized patients with a morphologic single right ventricle
to receive either a MBTS or RVPAS during the Norwood
procedure.8,10 The National Heart, Lung, and Blood
Institute-funded trial enrolled 555 subjects from 15 North
American centers from May 2005 to July 2008 through
the Pediatric Heart Network. The primary end point of the
trial was the rate of death or cardiac transplantation 12
months after randomization based on intention-to-treat
analysis. As reported previously,6 there were 72 events
(26.3%) (ie, 68 deaths and 4 transplantations) in the RVPAS
cohort, compared with 100 events (36.4%) (ie, 91 deaths
and 9 transplantations) among the subjects receiving an
MBTS. The group difference of 10.1% favored the RVPAS
(95% confidence interval, 17.8-2.4; P ¼ .01). The
nonintention-to-treat analysis, based on the actual shunt in
place at the conclusion of the Norwood procedure (MBTS
n ¼ 268 vs RVPAS n ¼ 281), showed similar results, with
a lower rate of death or cardiac transplantation at 12 months
in the RVPAS group (25.6% vs 37.3%; absolute reduction
of 11.7%; 95% CI, 19.4-4.0; P ¼ .003).
Findings in the SVR trial are consistent with previously
reported mortality rates of 7% to 19% for the Norwood
hospitalization and 4% to 15% between the Norwood
hospital discharge and the stage II operation (interstage
period).1-5 Despite the high mortality associated with
staged palliation for single ventricle lesions, little is
known about the specific causes, timing, and location of
deaths during the first year. Improved understanding of
the circumstances surrounding the mortality of these
infants may allow for refinements in management to
optimize outcomes for this challenging population of
patients. The SVR trial, which included prospective
follow-up of subjects, provides a unique opportunity to ex-
plore mortality-related events in this high-risk population.
The purpose of our report is to describe the subjects in
this well-defined cohort.
METHODS
Study Sample
Of the 555 subjects enrolled in the SVR trial, six were excluded from the
primary end point, yielding a final cohort of 549; 5 infants did not undergo
a Norwood procedure after randomization and 1 patient’s family withdrew
research consent following the Norwood procedure. The 549 eligible
subjects from the SVR trial formed the analytic cohort for this report.
Each participating center’s institutional review board approved the trial,908 The Journal of Thoracic and Cardiovascular Surgand written informed consent was obtained from one or both parents. Vital
status; date of death; a narrative of the circumstances surrounding the
death, including location; and, if performed, the autopsy results, were
collected as part of the SVR trial protocol. These data were extracted
from the trial database for analysis. Additional information, such as results
of the most recent echocardiogram before death, was obtained as needed to
assist adjudication of the cause of death.
Adjudication Process
All deaths that occurred during the 12 months following randomiza-
tion were reviewed by a 5-member panel recruited from participating
SVR centers and the National Heart, Lung, and Blood Institute. The panel
included the SVR study chairman, a pediatric cardiologist, a pediatric
cardiac intensivist, and 2 pediatric cardiac surgeons. A list of cause of
death categories (Table 1) was developed by the panel, with input from
the SVR trial subcommittee, which included a representative from each
participating center. Further subcategorization within categories, beyond
for example ‘‘cardiovascular’’ to ‘‘shunt,’’ was not practical due to the
relatively small numbers of deaths within each category. In addition, al-
though it was often possible to assign a death to the ‘‘cardiovascular’’
category, it was extremely rare to have definite objective data pointing
to a more specific cause; for example, to a shunt thrombosis defined at
autopsy or on angiography.
Each panel member reviewed the information on each death indepen-
dently and assigned the death to 1 category. The panel discussed each
case via conference call to arrive at a consensus decision on the final cate-
gorization. If death occurred in an operating room, an intensive care unit,
a general care ward, an emergency room, at another facility, or at home
was recorded. The number of deaths in which care was withdrawn and
the number of cases with an autopsy were also noted.
A subgroup of interest included those subjects who died unexpectedly
after being discharged to home in good condition. An entry was recorded
if the patient had been doing well at home and suffered an acute event
leading to death. In addition, the medical charts were reviewed to inves-
tigate if any prodrome, such as poor oral intake or irritability, could be
identified. For the purposes of our analysis, a prodrome was defined as
a sign or symptom that occurred in the days preceding an event that could
have offered the potential for intervention to prevent death (eg, not in-
cluding a patient who became acutely cyanotic and then immediately
arrested).
Statistical Methods
Comparisons by shunt type were conducted according to the shunt in
place at the end of the Norwood procedure (ie, nonintention-to-treat). A
small number of pulmonary parenchymal, pulmonary vascular, and airway
deaths occurred and these were combined into 1 single pulmonary cate-
gory. Multisystem organ failure with infectious etiology and with other/un-
known etiology was also combined into a single category for similar
reasons. The Fisher exact test was used to compare the distributions of
cause of death by shunt type and by time period. A secondary analysis
was performed comparing the proportions of patients with cardiovascular
vs noncardiovascular death by shunt type. Comparisons of the cause of
death distributions by shunt type were also conducted within strata defined
by the presence vs absence of aortic atresia, and the presence vs absence of
obstructed pulmonary venous return, which were prespecified, prerandom-
ization strata in the SVR trial. Patient characteristics of thosewith unknown
cause of deathwere compared with thosewith a known cause of death using
the Student t test for continuous variables and the Fisher exact test for cat-
egorical variables. The median time of death was compared by shunt type
using the Wilcoxon rank sum test. Survival probabilities up to 1 year post-
randomization by shunt type were estimated using the Kaplan-Meier
method. Qualifying events included posttransplant deaths. All statistical
analyses were conducted using SAS version 9.3 (2011; SAS Institute,
Cary, NC).ery c October 2012
TABLE 1. Cause of death categories
Body system Guidelines
Cardiovascular Including heart, great vessels,
pulmonary veins, venae cavae, and
shunt
Pulmonary
Parenchymal eg, Bronchopulmonary dysplasia
Vascular eg, Pulmonary vascular obstructive
disease
Airway eg, Airway occlusion, bronchospasm
Gastrointestinal/hepatic Including necrotizing enterocolitis
Renal
Hematologic Including documented
hypercoagulable state
Surgical complication Documented technical misadventure
directly related to surgical
procedure (ie, lacerating the aorta
or heart on resternotomy, autopsy
proven stenosis of the coronary
anastomosis). Surgical
complications would not include
routine risks of surgery.
Catheterization complication Documented technical complication
directly related to catheterization
procedure (ie, perforating the left
atrium, or rupturing the pulmonary
artery). Catheterization
complications would not include
routine risks of catheterization.
Multisystem organ failure
Infectious etiology
Unknown/other etiology
Infectious
Other Used when a specific cause of death is
known, but it does not meet one of
the categories on the list (eg, car
accident).
Unknown The cause of death is unknown due to
lack of information, or a single
causative etiology cannot be
determined.
TABLE 2. Cause of death in the overall cohort and by shunt type
Cause of death
Overall (%)
(N ¼ 164)
MBTS (%)
(n ¼ 95)
RVPAS (%)
(n ¼ 69)
Cardiovascular 68 (42) 36 (38)* 32 (46)*
Unknown 40 (24) 30 (32)* 10 (14)*
MSOF, any etiology 15 (9) 7 (7)* 8 (12)*
Infection 11 (7) 6 (6)* 5 (7)*
Surgical complication 10 (6) 5 (5)* 5 (7)*
Pulmonary, any etiology 9 (6) 5 (5)* 4 (6)*
Other 6 (4) 2 (2)* 4 (6)*
Neurological 2 (1) 2 (2)* 0 (0)*
GI/hepatic 2 (1) 1 (1)* 1 (2)*
Renal 1 (1) 1 (1)* 0 (0)*
Total for all causes other
than cardiovascular
96 (58) 59 (62)y 37 (54)y
Data are presented as number (%). Percentages may not total 100% due to rounding.
MBTS, Modified Blalock-Taussig shunt; RVPAS, right ventricle-to-pulmonary artery
shunt; MSOF, multisystem organ failure; GI, gastrointestinal. *P ¼ .27 for cause of
death by shunt type. yP ¼ .34 for cause of death by shunt type.
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DRESULTS
Adjudication Process
The adjudication process was validated by readjudicating
30 randomly selected deaths. The panel used the same pro-
cedure as described above to categorize each death. The
prespecified criterion for acceptable agreement was a k
statistic value of 0.5 for the lower limit of a 1-sided 85%
confidence interval. The k statistic was 0.82 (lower 85%
confidence limit, 0.74), demonstrating very good agreement
between the original cause of death category and the new
category for the 30 cases.
Mortality
One-year follow-up was available on all subjects. Among
the 549 subjects, there were 164 deaths (30%) during theThe Journal of Thoracic and Ca12 months following randomization. These included the
159 deaths accounted for in the primary outcome from the
SVR trial (ie, death or transplantation at 12 months postran-
domization), as well as an additional 5 deaths occurring
after transplantation but within the 12-month period. By
shunt type at the end of the Norwood procedure, there
were 69 of 274 deaths (25%) in the RVPAS group and 95
of 275 deaths (35%) in the MBTS group at 12 months post-
randomization. As in the nonintention-to-treat analysis for
the primary end point of death or transplantation from the
SVR trial, the difference in the nonintention-to-treat analy-
sis for mortality alone was statistically significant, favoring
the RVPAS (P ¼ .007).
Cause of Death
For the overall cohort, as well as when stratified by shunt
type, the most common causes of death were of cardiovas-
cular origin, followed by an unknown cause and multisys-
tem organ failure of any etiology (Table 2). To determine
if subjects in the unknown category should remain in
the analyses, comparisons were conducted between sub-
jects with a known (n¼ 124) vs an unknown cause of death
(n ¼ 40). Subjects in the unknown category had a signifi-
cantly higher mean birth weight (P ¼ .009), were less fre-
quently born at<37 weeks gestation (P ¼ .02), and were
less likely to have received a RVPAS (P ¼ .02). Exclusion
of subjects falling into the unknown cause of death category
would therefore result in a biased analytic cohort that is
more likely to have a RVPAS and on average has worse
birth outcomes. Therefore, subjects in the unknown cate-
gory were retained in the analysis.
There was no difference in the distribution of the causes
of death between the 2 shunt types (P ¼ .27) (Table 2).
Similarly, when cause of death was analyzed by comparing
cardiovascular causes with all noncardiovascular etiologies,rdiovascular Surgery c Volume 144, Number 4 909
TABLE 3. Cause of death by the presence or absence of aortic atresia or obstructed pulmonary venous return, overall, and by shunt type
Cause of death
Overall
(N ¼ 164)
(P ¼ .30)
MBTS
(n ¼ 95)
(P ¼ .25)
RVPAS
(n ¼ 69)
(P ¼ .75)
Overall
(N ¼ 164)
(P ¼ .26)
MBTS
(n ¼ 95)
(P ¼ .34)
RVPAS
(n ¼ 69)
(P ¼ .26)
AA
(n ¼ 103)
No AA
(n ¼ 61)
AA
(n ¼ 62)
No AA
(n ¼ 33)
AA
(n ¼ 41)
No AA
(n ¼ 28
OPVR
(n ¼ 14)
No OPVR
(n ¼ 150)
OPVR
(n ¼ 11)
No OPVR
(n ¼ 84)
OPVR
(n ¼ 3)
No OPVR
(n ¼ 66)
Cardiovascular 41 (40) 27 (44) 24 (39) 12 (36) 17 (42) 15 (54) 6 (43) 62 (41) 5 (46) 31 (37) 1 (33) 31 (47)
Unknown 29 (28) 11 (18) 22 (36) 8 (24) 7 (17) 3 (11) 1 (7) 39 (26) 1 (9) 29 (34) 0 (0) 10 (15)
MSOF, any etiology 9 (9) 6 (10) 4 (6) 3 (9) 5 (12) 3 (11) 1 (7) 14 (9) 1 (9) 6 (7) 0 (0) 8 (12)
Infection 8 (8) 3 (5) 4 (6) 2 (6) 4 (10) 1 (4) 1 (7) 10 (7) 1 (9) 5 (4) 0 (0) 5 (7)
Surgical complication 7 (7) 3 (5) 4 (6) 1 (3) 3 (7) 2 (7) 3 (21) 7 (5) 2 (18) 3 (4) 1 (33) 4 (6)
Pulmonary, any etiology 4 (4) 5 (8) 1 (2) 4 (12) 3 (7) 1 (4) 1 (7) 8 (5) 1 (9) 4 (5) 0 (0) 4 (6)
Other 2 (2) 4 (7) 1 (2) 1 (3) 1 (2) 3 (11) 1 (7) 5 (3) 0 (0) 2 (2) 1 (33) 3 (5)
Neurologic 0 (0) 2 (6) 0 (0) 0 (0) 0 (0) 2 (6) 0 (0) 2 (1) 0 (0) 2 (2) 0 (0) 0 (0)
GI/hepatic 1 (1) 0 (0) 1 (2) 0 (0) 1 (1) 0 (0) 0 (0) 2 (1) 0 (0) 1 (1) 0 (0) 1 (2)
Renal 1 (2) 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 1 (1) 0 (0) 1 (1) 0 (0) 0 (0)
Data are presented as number (%). Percentages may not total 100% due to rounding. AA, Aortic atresia; OPVR, obstructed pulmonary venous return;MBTS, modified Blalock-
Taussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt; MSOF, multisystem organ failure; GI, gastrointestinal.
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D no difference between shunt types was found (P ¼ .34)
(Table 2). There were also no significant differences in
causes of death when further stratifying by the presence
or absence of aortic atresia and by the presence or absence
of obstructed pulmonary venous return (Tables 3 and 4).Timing of Death
The timing of death was analyzed for the entire cohort
and for each shunt type. For the overall cohort, the median
age at death for subjects dying during the first year was 1.6
months (interquartile range [IQR], 0.6-3.7 months). The
median age at death did not differ by shunt type (1.6 months
[IQR, 0.8-3.5 months] for the MBTS group vs 1.7 months
[IQR, 0.4-4.2 months] for the RVPAS group; P ¼ .78).
The timing of death was also analyzed by 4 clinically rel-
evant time periods: randomization to Norwood hospitaliza-
tion discharge, Norwood hospitalization discharge to stage
II admission, stage II admission to stage II discharge, and
stage II discharge to 12 months (Table 5). The majority of
deaths during the first year for the entire cohort, as well
as for each shunt type, occurred during the Norwood hospi-
talization; the next highest number of deaths was in theTABLE 4. Cardiovascular deaths vs all other causes by the presence or ab
and by shunt type
Cause of
death
Overall
(N ¼ 164)
(P ¼ .62)
MBTS
(n ¼ 95)
(P ¼ .99)
RVPAS
(n ¼ 69)
(P ¼ .34)
AA
(n ¼ 103)
No AA
(n ¼ 61)
AA
(n ¼ 62)
No AA
(n ¼ 14)
No OPVR
(n ¼ 150)
OP
(n ¼
Cardiovascular 41 (40) 27 (44) 24 (39) 6 (43) 62 (41) 5 (
Other cause or
unknown
62 (60) 34 (56) 38 (61) 8 (57) 88 (59) 6 (
Data are presented as n (%). Percentages may not total 100% due to rounding. AA, Aortic
artery shunt; OPVR, obstructed pulmonary venous return.
910 The Journal of Thoracic and Cardiovascular Surginterstage period between the Norwood hospitalization
discharge and the stage II operation. The overall timing of
death by the four time intervals differed significantly by
shunt type (P ¼ .02), with more early deaths in the
MBTS group and more late deaths in the RVPAS group.
Within the individual 4 time periods, there were no statisti-
cally significant differences in the timing of death by shunt
type.
The mortality rate during the Norwood Hospitalization
was 16% (88 out of 549). During the interstage period
from the Norwood hospitalization discharge and the stage
II admission, the mortality rate was 11.7% (54 out of 461).
The hospital mortality for the stage II operation was 3.9%
(16 out of 407), and for the period from stage II discharge
to 12 months the mortality rate was 1.5% (6 out of 391).Location and Other Aspects of Death
The location of each death was recorded as occurring at
a SVR trial member institution, at an outside hospital, or
at home (Table 6). The most common location of death
for the overall cohort was at a SVR hospital (74%), fol-
lowed by death at home (13%). The inpatient deaths,sence of aortic atresia or obstructed pulmonary venous return, overall
Overall
(n ¼ 164)
(P ¼ .99)
MBTS
(n ¼ 95)
(P ¼ .74)
RVPAS
(n ¼ 69)
(P ¼ .99)
VR
11)
OPVR
(n ¼ 14)
No OPVR
(n ¼ 150)
OPVR
(n ¼ 11)
No OPVR
(n ¼ 84)
OPVR
(n ¼ 3)
No OPVR
(n ¼ 66)
46) 6 (43) 62 (41) 5 (46) 31 (37) 1 (33) 31 (47)
55) 8 (57) 88 (59) 6 (55) 53 (63) 2 (67) 35 (53)
atresia;MBTS, modified Blalock-Taussig shunt; RVPAS, right ventricle-to-pulmonary
ery c October 2012
TABLE 5. Timing of death, overall cohort and by shunt type
Time interval Overall MBTS* RVPAS*
Median age at death
Overall
(N ¼ 164)
MBTS
(n ¼ 95)
RVPAS
(n ¼ 69) P valuey
Randomization to Norwood discharge 88 (54) 48 (51) 40 (58) 0.69 (0.3-1.4) 0.88 (0.4-1.5) 0.46 (0.2-1.3) .06
Norwood discharge to Stage II admission 54 (33) 39 (41) 15 (22) 3.0 (1.8-4.3) 2.6 (1.5-4.2) 3.4 (2.8-5.0) .07
Stage II admission to Stage II discharge 16 (10) 6 (6) 10 (14) 5.3 (3.8-6.5) 4.7 (3.5-5.7) 5.8 (4.2-6.8) .43
Stage II discharge to 12 mo 6 (4) 2 (2) 4 (6) 8.0 (6.6-9.2) 6.5 (3.7-9.2) 8.0 (7.2-9.0) .83
Total 164 (100) 95 (58) 69 (42) 1.6 (0.6-3.7) 1.6 (0.8-3.5) 1.7 (0.4-4.2) .78
Data are presented as number (%) (percentages may not total 100% due to rounding) or months (interquartile range). MBTS, Modified Blalock-Taussig shunt; RVPAS, right
ventricle-to-pulmonary artery shunt. *P ¼ .02 for timing of death by shunt type. yP values are from Wilcoxon rank sum test.
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further categorized as having occurred in the operating
room, the intensive care unit, the general care ward, or the
emergency room, with the majority (71%) occurring in
the intensive care unit (Table 5). In 37% of deaths (61 out
of 164), care was withdrawn and in 24% (40 out of 164)
a limited or full autopsy was performed.
In 29 subjects (18%), death was categorized as unex-
pected, with the initial events occurring outside of a hospital
(death may ultimately have occurred in a hospital). Twelve
deaths (ie, 41% of unexpected deaths, 7% of all deaths in
the SVR trial) were preceded by a prodrome, 16 were not
preceded by a prodrome, and in 1 death the presence of
a prodrome was unknown. Of those with a prodrome, 4
were described as having poor oral intake or vomiting; 3
as having fussiness; 2 as having diarrhea; 1 as having
cyanosis; 1 as having a combination of poor oral intake,
fussiness, and diarrhea; and 1 with a combination of fever
and increased work of breathing. Of those with a prodrome,
3 subjects had been evaluated by their local physician for
their symptoms.DISCUSSION
The mortality of infants enrolled in the SVR trial is sim-
ilar to previously published reports.1-6 The first year of life
has a high risk for mortality, especially during
hospitalization related to the Norwood procedure and the
interstage period leading up to the stage II procedure.TABLE 6. Location of patient death (overall N ¼ 164; inpatient
n ¼ 140)
Location of death n (%)
SVR trial member hospital 121 (74)
Home 22 (13)
Outside hospital 19 (12)
Unknown 2 (1)
Any hospital intensive care unit 99 (71)
Unknown location in a hospital 21 (15)
Hospital emergency room 10 (7)
Hospital operating room 8 (6)
Hospital general care floor 2 (1)
SVR, Single ventricle reconstruction.
The Journal of Thoracic and CaThis is the first systematic report of the causes of death in
a large cohort of infants with hypoplastic left heart
syndrome and related single ventricle lesions undergoing
staged repair. Evaluating the circumstances surrounding
these mortalities may in turn identify potential areas
where changes in medical management could improve
outcomes.
The results of our analysis of mortality during the first
year after the Norwood procedure showed that the predom-
inant cause of death was cardiovascular and those with an
MBTS were more likely to die during the Norwood hospi-
talization than thosewith an RVPAS. The majority of deaths
occurred in a hospital, and of those, the majority occurred in
an intensive care unit. In more than one-third of cases, the
family requested that care be withdrawn.Cause of Death
It is not surprising that the primary cause of death was
cardiovascular. In many of the cases in the cardiovascular
category, the underlying mechanism was myocardial failure
and low cardiac output. In addition, the majority of deaths
occurred during hospitalization for the Norwood procedure.
This combination of findings suggests that better forms of
myocardial protection or better ways to enhance postopera-
tive myocardial performance are needed.
Surgical complicationswere the fifthmost common cause
of death and provide another example of the potential
benefit of modification of perioperative management or
technique. Although beyond the scope of our study, the
rate of death due to surgical complications could be com-
pared by practice patterns or by center in an attempt to iden-
tify the common practices associated with the lowest
surgical mortality rates. These best practices could then be
disseminated to all institutions. Successful approaches for
identifying and sharing best practices at high-performing
centers have been established in other disciplines, such as
adult cardiovascular surgery, infection control, and cystic fi-
brosis, and are now beginning to be applied in congenital
heart surgery, as well.11-14
The cause of death, either overall or when stratified by
shunt type, was not affected by the presence or absence of
aortic atresia or obstructed pulmonary venous return. Thisrdiovascular Surgery c Volume 144, Number 4 911
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hypothesized that aortic atresia would have contributed to
the preponderance of cardiovascular-related deaths and
obstructed pulmonary venous return to a high incidence of
pulmonary vascular category deaths. Whether or not aortic
atresia represents a risk factor for survival remains contro-
versial, with some centers reporting a correlation, whereas
others do not.15,16 The relationship of aortic atresia and
other potential risk factors to mortality in the SVR trial is
currently being analyzed. Obstructed pulmonary venous
return has also been inconsistently associated with
mortality in previous publications.16,17 Obstruction to
pulmonary venous return may be particularly important as
a patient progresses to the stage II and Fontan procedures,
where low pulmonary vascular resistance is crucial.17 Our
analysis was limited to the 12 months following randomiza-
tion and it is possible that the adverse effects of obstructed
pulmonary venous return may become evident only in later
follow-up. In addition, the relatively low incidence of
obstructed pulmonary venous return in the cohort of subjects
who died during the SVR trial period (n ¼ 14) limits the
power to detect differences.
Timing of Death
In the SVR trial, as in other reports, the highest risk of
dying during the first year was during hospitalization for
the Norwood procedure. However, the interval from Nor-
wood hospitalization discharge to the stage II procedure is
a high-risk period, as well.5,6,18 Overall, 33% of deaths
(54 out of 164) during the 12-month duration of the trial
occurred during this interstage period, representing an over-
all trial mortality rate between the first and second stages of
11.7% (54 of 461). Whether or not home monitoring pro-
grams can affect this interstage mortality remains contro-
versial. Recently, some institutions have reported small
case series demonstrating a decrease in interstage mortality
with the implementation of a formal home monitoring
program, although others have not.18-20 Furthermore, it
remains unknown if these patients would have breached
criteria of a home monitoring program or if immediate
hospital admission or any intervention would have been
successful in preventing death.
Location and Other Aspects of Death
Analysis of the location of death provides another op-
portunity to improve outcomes. Twenty percent of deaths
(32 out of 164) occurred either at home or in a hospital
emergency department. Of these outpatient deaths, 29
were unexpected, occurring in patients who were otherwise
doing well. This group of patients is of particular interest
because their deaths may have been potentially prevent-
able, if an early warning signal could have been detected.
The 12 subjects who manifested a prodrome before their
fatal event may represent a subset in which such a signal912 The Journal of Thoracic and Cardiovascular Surgwas present. It is not possible to know, from the level of
data available for our analysis, if other subjects who died
unexpectedly also had prodromes that could not be identi-
fied retrospectively. In addition, it is unknown how many
surviving subjects in the SVR trial had similar signs and
symptoms at home without a subsequent lethal event.
One may postulate that improvements in parent or local
physician education may have averted some deaths. A
recent survey of 376 emergency department physicians de-
termined that most (72%) were unsure of the acceptable
range of arterial oxygen saturation for infants with a single
ventricle, and 58% were ‘‘uncomfortable’’ or ‘‘worried’’
about their treatment.21 Despite these concerns, 59%
deemed education in single ventricle physiology as low
priority, likely due to the low frequency of encounters
with these unique patients.CONCLUSIONS
Remarkable progress has been made in the care of
patients with single ventricles with systemic outflow ob-
struction, a universally fatal lesion just 3 decades ago.
However, despite this success, there continue to be high
rates of attrition throughout the first year of life. Analysis
of the cause of death of these infants may be useful in de-
creasing this mortality rate. The data regarding the etiology
of the deaths in the SVR trial suggest that efforts to
improve postoperative myocardial performance may be
helpful in improving outcomes. Analyzing variations in
care and developing best practices may also decrease mor-
tality. The continued high interstage attrition, as well as the
frequent finding of a prodrome before unexpected deaths,
may suggest that a home monitoring program or providing
parents and primary care physicians with a list of concern-
ing signs and symptoms may be helpful. Through better
understanding of the mechanisms of death, we hope to de-
vise improved surgical techniques, inpatient and outpatient
management, and family and health care provider educa-
tion to continue to optimize outcomes for this challenging
group of patients.References
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